Key Summary Points {#FPar1}
==================

**Why carry out this study?** Perianal fistulas are associated with significant morbidity and impaired quality of life. However, their prevalence in Europe is unknown.**What was learned from the study?** This article describes two independent literature reviews showing a prevalence of perianal fistulas in Europe of 1.69 per 10,000 population. Cryptoglandular infection and Crohn's disease were the predominant aetiologies, with prevalence of 0.86 and 0.76 per 10,000 population, respectively. Analyses of a large population-based database from the UK confirmed the robustness of this estimate. The data indicate that perianal fistulas meet the criterion to be considered a rare condition in Europe (prevalence less than 5 per 10,000 population established by the European Medicines Agency).

Introduction {#Sec1}
============

Fistulas are abnormal connections between two epithelialized surfaces \[[@CR1], [@CR2]\]. An external fistula is defined as one that connects an internal organ and the skin surface \[[@CR3]\]. According to the most widely accepted definition, an anal fistula is an external fistula that creates an abnormal connection between the anorectum and perianal epithelium \[[@CR4]--[@CR7]\]. Anal fistulas are associated with significant clinical manifestations (e.g., local pain, phlogosis, purulent drainage, and incontinence) and impaired health-related quality of life \[[@CR6]\]. Although surgery of anal fistulas is one of the most common operations performed by colorectal surgeons and new therapies for this condition make epidemiologic data relevant for heathcare planning, the prevalence of this condition remains largely unknown.

Most anal fistulas are either of cryptoglandular origin or secondary to Crohn's disease (CD), although a variety of other etiologies have been identified, including infection, trauma, cancer, and congenital malformation. Whereas cryptoglandular anal fistulas are assumed to be caused by an infection of the anal glands \[[@CR6], [@CR8]\], those related to CD appear to be a consequence of anorectal lesions produced by the transmural inflammatory process \[[@CR9], [@CR10]\].

The aim of the present study was to estimate the prevalence of anal fistulas in Europe overall and by etiology.

Methods {#Sec2}
=======

For this study, the most common definition of anal fistula was used (abnormal connection between the anorectum and perianal skin). Other suppurating perianal/perirectal conditions are beyond the scope of this work.

Literature Review {#Sec3}
-----------------

To optimize the probability of retrieving relevant articles, two separate systematic literature searches were conducted. The first was a targeted search of the MEDLINE database, performed using a series of specific search terms covering the different etiologies of anal fistulas. The second employed more generic search terms, and included studies indexed in MEDLINE, Embase, and Cochrane databases. In this case, search terms referred to anal fistulas, but not to their specific etiologies. The full search algorithms are available in Supplementary Material Files 1 and 2.

The two searches, completed in December 2017, were conducted independently, and the retrieved titles and abstracts were screened by two independent reviewers. No restrictions were placed on the type of study or publication included, with selection based solely on the relevance of data reported to the study question. Eligible studies were those published in English, reporting European population-based epidemiologic data on anal fistulas, with an appropriate case definition, from which prevalence could be estimated. Potentially relevant articles were subjected to full text review and those fulfilling the aforementioned selection criteria were used to estimate the prevalence of anal fistulas.

Bibliographies of the selected articles were screened to identify any additional sources of relevant data.

For etiologies in which only incident cases were reported or could be derived, prevalence was estimated from the reported incidence and the median duration of the condition, based on the following equation relating to both variables \[[@CR11]\]:$$\documentclass[12pt]{minimal}
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For etiologies leading to fistulas of 1-year duration or less, incidence was assumed to represent a conservative estimate of prevalence.

The overall prevalence of CD-related anal fistulas was calculated as the mean prevalence of anal fistulas in the Crohn's population, obtained from population-based, cross-sectional studies, multiplied by the weighted mean prevalence of CD/10,000 population in Europe, obtained from studies published over the last 10 years (2008--2017; Supplementary Material File 3) \[[@CR12]--[@CR31]\]. The weighted mean prevalence of Crohn's disease was calculated on the basis of the 2017 mid-year populations \[[@CR32]\].

The literature review is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

While the study was not captured in a database, the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines \[[@CR33]\] were followed as closely as possible to ensure reporting transparency. Given the nature of the data collected, it was deemed inappropriate to attempt a meta-analysis of the extracted data, and this study is a systematic review of the literature only.

Population-Based Database Analysis {#Sec4}
----------------------------------

To validate the estimates derived from the literature, the prevalence of anal fistulas among patients in a population-based healthcare database in the UK was compared with the European population. This analysis employed The Health Improvement Network (THIN) \[[@CR34]\], a primary care database containing electronic medical records for more than 3 million active patients. Relevant diagnostic and surgical codes were used to identify cases of anal fistula (Supplementary Material File 4). To account for the longer duration of anal fistulas in CD compared with non-CD etiologies, prevalence estimates were calculated using an assumed duration of at most 4 years for anal fistulas related to CD and at most 12 months for etiologies other than CD, following clinical judgement and published data \[[@CR35]\]. Anal fistulas in CD were defined as having a CD diagnosis at any time before or up to 4 years after the anal fistula diagnosis, as anal fistulas may be the first manifestation of CD. Prevalence was calculated on the basis of the numbers of prevalent cases of anal fistulas and active patients as of July 1 of each year.

To facilitate standardization to the UK and European population reference sets, prevalence estimates were stratified by age and sex. The latest population reference sets for the UK (2016) \[[@CR36]\] and Europe (2013) \[[@CR37]\] were then used to extrapolate prevalence estimates to the UK and European populations, respectively.

The population-based database analysis was reviewed and approved by the THIN Scientific Review Committee (SRC 18THIN006). The study conformed to the Helsinki Declaration of 1964, as revised in 2013, and Springer's ethical policy.

Results {#Sec5}
=======

The two literature searches yielded totals of 596 and 356 publications, of which 26 and 6, respectively, were found to provide epidemiologic data related to anal fistulas, with an overlap of six references. After full text review, 16 studies in total were found suitable to be used as data sources to estimate the prevalence of anal fistulas (Fig. [1](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). Where recorded, the included cohorts were predominantly male and aged 30--50 years (Table [1](#Tab1){ref-type="table"}) \[[@CR38]--[@CR53]\]. The ten excluded studies and the corresponding reasons for exclusion are listed in Supplementary Material File 5.Fig. 1Study flow diagram corresponding to the **a** targeted literature search and **b** systematic literature searchTable 1Studies used as source of data in the analysis of the prevalence of anal fistulas in EuropeEtiologyStudyRegionDesignNumber of patients includedMale (%)Average age (years)Estimation made from the reported dataCryptoglandularSainio 1984 \[[@CR38]\]FinlandRetrospective analysis4586338^a^Prevalence of cryptoglandular anal fistulaCrohn's diseaseSEESG-CD 1999 \[[@CR39]\]SpainCross-sectional observation study6354833Prevalence of Crohn's-related anal fistulaChaparro et al. 2011 \[[@CR40]\]SpainPopulation-based cohort study23915541^b^Prevalence of Crohn's-related anal fistulaGöttgens et al. 2017 \[[@CR41]\]NetherlandsPopulation-based cohort study11623738^c^Prevalence of Crohn's-related anal fistulaGeorgiadou et al. 2019 \[[@CR42]\]GermanyCross-sectional claims database analysis13,346NRNRPrevalence of Crohn's-related anal fistulaTraumaSielezneff et al. 1997 \[[@CR43]\]FranceRetrospective cohort study11347148Prevalence of trauma-related anal fistula (iatrogenic)Rosa et al. 2005 \[[@CR44]\]ItalyRetrospective cohort study3746042^b^Prevalence of trauma-related anal fistula (iatrogenic)Sultan et al. 2010 \[[@CR45]\]FranceProspective study1508150Prevalence of trauma-related anal fistula (iatrogenic)Bouchard et al. 2013 \[[@CR46]\]FranceProspective study6334348^b^Prevalence of trauma-related anal fistula (iatrogenic)Bjelanovic et al. 2016 \[[@CR47]\]SpainProspective observational study4026746Prevalence of trauma-related anal fistula (iatrogenic)Milito et al. 2017 \[[@CR48]\]ItalyRetrospective cohort study1000NR19--80^d^Prevalence of trauma-related anal fistula (iatrogenic)Systemic infectionScieux et al. 1989 \[[@CR49]\]FranceCase series2710017--73^d^Prevalence of infection-related anal fistula (lymphogranuloma venereum)Alvarez Conde et al. 1992 \[[@CR50]\]SpainCases report and reviewNANANAPrevalence of infection-related anal fistula (tuberculosis)Gupta et al. 2005 \[[@CR51]\]NRReviewNANANAPrevalence of infection-related anal fistula (tuberculosis)CancerJensen et al. 1988 \[[@CR52]\]DenmarkCase series213870^b^Prevalence of adenocarcinoma-related anal fistulaCongenitalCuschieri 2001 \[[@CR53]\]EuropeEpidemiologic registry survey4.6 MNRNewbornsPrevalence of congenital anal fistula*M* million, *NA* not applicable, *NR* not reported, *SEESG*-*CD* Spanish Epidemiological and Economic Study Group on Crohn's disease^a^Only reported for nonspecific anal fistula (414 patients)^b^Median age^c^Mean age at time of CD diagnosis^d^Age range only reported

Anal Fistulas of Cryptoglandular Origin {#Sec6}
---------------------------------------

A single article provided data suitable to derive the prevalence of anal cryptoglandular fistulas. Sainio \[[@CR38]\] estimated the incidence among the residents of Helsinki, based on the number of patients hospitalized for surgery related to anal fistulas of cryptoglandular origin from 1969 to 1978. Although conducted in a hospital setting, the study provided a population-based perspective, as surgical intervention is the primary treatment modality in virtually all patients with this type of anal fistula. The reported annual incidence was 0.86/10,000 population. Given the limited duration of the condition (on average up to 1 year according to clinical experience), the reported incidence represents an acceptable estimate of the prevalence.

Crohn's Disease-Related Anal Fistulas {#Sec7}
-------------------------------------

The estimated prevalence of anal fistulas related to CD was based on four studies (Table [2](#Tab2){ref-type="table"}). A Spanish group conducted a cross-sectional study in 635 consecutive outpatients from 39 randomly selected clinics and hospitals \[[@CR39]\]. It reported perianal disease in 12.0% of patients with CD. Based on evidence suggesting that 50% of patients with CD and perianal involvement have perianal fistulas \[[@CR54]\], the estimated prevalence of anal fistulas in CD was 6.0%. Of note, these data can be considered population-based as the vast majority of patients with CD in Spain are diagnosed and followed in secondary and tertiary centers.Table 2Prevalence rates of anal fistulas among patients with Crohn's disease, derived from European studiesStudyDesignCohort sourceNumber of patients includedPrevalence (%)SEESG-CD 1999 \[[@CR39]\]Cross-sectional observation study39 hospitals throughout Spain6356.0Chaparro et al. 2011 \[[@CR40]\]Population-based cohort study11 hospitals in Madrid23914.32Göttgens et al. 2017 \[[@CR41]\]Population-based cohort studyPopulation-based IBD cohort in the Netherlands (IBD South Limburg registry)11624.49Georgiadou et al. 2019 \[[@CR42]\]Cross-sectional claims database analysisClaims data from several German company health insurance funds13,3463.38Total^a^4.55*IBD* inflammatory bowel disease, *SEESG*-*CD* Spanish Epidemiological and Economic Study Group on Crohn's disease^a^Weighted average

A second Spanish study evaluated the incidence of perianal fistulas in 2391 patients with CD treated in secondary and tertiary institutions, and reported an annual incidence of 1.2% \[[@CR40]\]. On the basis of the median duration of anal fistulas in patients with CD \[[@CR35]\], the annual incidence reported in the present study was multiplied by a median duration of 3.6 years, resulting in an estimated prevalence of 4.3% among the CD population.

In a Dutch population-based study evaluating anal fistulas in 1162 patients with CD, Göttgens et al. \[[@CR41]\] reported an incidence of 8.3% during the first year following initial diagnosis of CD and a cumulative incidence of 15.8% at 10 years after diagnosis. Analysis of the data suggested that the cumulative incidence during years 2--10 after the initial diagnosis of CD (7.5%) was linear, yielding an annual incidence of 0.83% over this period. To estimate prevalence, annual incidence was derived from the annual incidence estimates of 8.3% during the first year after diagnosis and 0.83% during years 2--10 applied to the mean incidence and prevalence of CD (1.4/10,000 and 25.14/10,000 population, respectively; means of figures recently reported in two Dutch studies) \[[@CR22], [@CR23]\]. The resulting annual incidence of anal fistulas in patients with CD (0.31/10,000 population) was multiplied by the median duration of the condition (3.6 years), yielding an estimated prevalence of 1.13/10,000 population. Considering the aforementioned prevalence of CD in the Netherlands, it was concluded that the prevalence of anal fistulas in the CD population was 4.49%.

Finally, Georgiadou et al. \[[@CR42]\] performed a retrospective analysis of a German claims database that included 13,346 patients with CD. Among these patients, 451 had a concurrent diagnosis of perianal fistula, suggesting an overall prevalence of 3.38%.

The mean prevalence of anal fistulas in CD across the four studies was 4.55%. Extrapolation to the European population using a weighted mean prevalence of CD of 16.63/10,000 population (Fig. [2](#Fig2){ref-type="fig"}) yielded an estimated prevalence of CD-related anal fistulas of 0.76/10,000 population. Based on a median duration of 3.6 years, the estimated annual incidence of CD-related anal fistulas was 0.21/10,000 population.Fig. 2Reported prevalence of Crohn's disease in Europe by country published over the last 10 years (2008--2017). Rates are per 10,000 population

Trauma-Induced Anal Fistulas {#Sec8}
----------------------------

Six studies provided data on the prevalence of anal fistulas related to iatrogenic trauma, all of which assessed the frequency of anal fistulas subsequent to hemorrhoidectomy (Table [3](#Tab3){ref-type="table"}) \[[@CR43]--[@CR48]\].Table 3Prevalence rates of anal fistulas among patients undergoing hemorrhoidectomy, derived from European studiesStudyDesignCohort sourceNumber of patients includedPrevalence (%)Sielezneff et al. 1997 \[[@CR43]\]Retrospective cohort studyA French hospital (1975--1990)11341.2Rosa et al. 2005 \[[@CR44]\]Retrospective cohort studyA UK hospital (1983--2002)3740.5Sultan et al. 2010 \[[@CR45]\]Prospective studyA French hospital (2001--2006)1500.67Bouchard et al. 2013 \[[@CR46]\]Prospective studyMultiple hospitals across France (2007--2008)6330.16Bjelanovic et al. 2016 \[[@CR47]\]Prospective observational studyA surgical center in Spain (2010--2014)4021.2Milito et al. 2017 \[[@CR48]\]Retrospective cohort studyAn Italian hospital (2001--2014)10000.3Total^a^0.69^a^Weighted average

The weighted mean frequency of anal fistulas reported as a complication of hemorrhoidectomy in the studies included in this analysis was 0.69%. Based on an estimated annual frequency of 4.5 hemorrhoidectomies/10,000 population derived from studies in Germany and England \[[@CR55], [@CR56]\], the estimated incidence of post-hemorrhoidectomy anal fistulas in Europe was 0.31/10,000 population. Given the short duration of the condition, this incidence represents a conservative estimate of the prevalence of anal fistulas following hemorrhoidectomy.

Anal Fistulas Related to Other Etiologies {#Sec9}
-----------------------------------------

Five studies were identified with suitable data to facilitate estimation of the prevalence of anal fistulas related to other etiologies, including infection, cancer, and congenital malformation \[[@CR49]--[@CR53]\]. Table [4](#Tab4){ref-type="table"} summarizes the estimated prevalence of these etiologies of anal fistulas based on the studies included in this analysis.Table 4Estimated prevalence rates of anal fistulas related to etiologies other than Crohn's disease and cryptoglandular infectionEtiologyPrevalence (per 10,000 population)Infection0.016Trauma0.031Cancer0.02Congenital0.01Total0.078

Three studies reporting suitable data on anal fistulas related to infection were identified, including two reports on anal fistulas in patients with tuberculosis and one case series in patients with lymphogranuloma venereum \[[@CR49]--[@CR51]\]. According to the most recent estimate from the European Centre for Disease Prevention and Control, the prevalence of tuberculosis in Europe is 1.65/10,000 population \[[@CR57]\]. Alvarez Conde et al. \[[@CR50]\] reported that 0.7% of patients with tuberculosis have perianal involvement, which corresponds to a prevalence of 0.012/10,000 population in Europe. Among these patients, anal fistulas were the most common presentation, occurring in 80--91% \[[@CR51]\], suggesting a prevalence of tuberculosis-related anal fistulas of 0.009--0.011 per 10,000 population, with a median of 0.1/10,000. In a case series of 27 patients with lymphogranuloma venereum, Scieux et al. \[[@CR49]\] observed two cases of anal fistulas (7.4%). Based on the reported prevalence of 0.08 cases of lymphogranuloma venereum/10,000 in Europe \[[@CR58]\], the estimated prevalence of anal fistulas related to lymphogranuloma venereum was 0.006/10,000 population. Combined with the estimated prevalence of tuberculosis-related fistulas, these data indicate a prevalence of anal fistulas related to infection of 0.016/10,000 population.

A single article reporting data on anal fistulas in patients with anal adenocarcinoma met the criteria for inclusion. In a case series of 21 patients with anal adenocarcinoma, Jensen et al. \[[@CR52]\] reported that anal fistulas occurred in 23.8%. Assuming a prevalence of 0.11 cases of anal adenocarcinoma/10,000 population in Europe \[[@CR59]\], this corresponds to a prevalence of anal adenocarcinoma-related fistulas of 0.026/10,000 population. Considering that a proportion of anal adenocarcinoma-related fistulas occur in patients with CD, the prevalence of these fistulas in the non-CD population has been calculated by subtracting the mean estimated prevalence of fistula-related anal cancers in CD in Europe based on published data (0.006/10,000 population) \[[@CR60]--[@CR62]\], resulting in an estimated prevalence of 0.02/10,000 population.

The literature searches retrieved one suitable article on congenital anal fistulas. In a 2001 European epidemiologic study, Cuschieri et al. \[[@CR53]\] reported a prevalence of 1.04 congenital anal fistulas/10,000 live births. Extrapolation of the estimate to the European Union population using the most recent data for the annual number of live births (5.1 million) \[[@CR63]\] and the total population (508.5 million) \[[@CR63]\] resulted in an estimated prevalence of 0.01/10,000 population.

Overall Prevalence of Anal Fistulas in Europe {#Sec10}
---------------------------------------------

The overall prevalence of anal fistulas in Europe, estimated as the sum of the estimated prevalence for all etiologies, was 1.69/10,000 population (Table [5](#Tab5){ref-type="table"}). CD and cryptoglandular infection were the predominant etiologies, accounting for more than 95% of all cases. In comparison, the overall incidence of anal fistulas in Europe was 1.15/10,000 population.Table 5Estimated prevalence and incidence of anal fistulas in EuropeEtiologyPrevalence (per 10,000 population)Proportion of prevalent cases (%)Incidence (per 10,000 population)Proportion of incident cases (%)Cryptoglandular0.8650.80.8674.9Crohn's disease0.7644.60.2118.3Other^a^0.0784.60.0786.8Total1.69100.01.15100.0^a^Includes infections, trauma, anal adenocarcinoma, and congenital malformation

Population-Based Database Analysis {#Sec11}
----------------------------------

The results of the population-based database analysis are summarized in Table [6](#Tab6){ref-type="table"}. Comparison of data from the UK THIN database with the European population yielded a standardized prevalence of 1.83 anal fistulas/10,000 population (95% confidence interval 1.68--1.98) in 2017, with a range of 1.83--2.36/10,000 population during the 4-year study period. The close agreement between the estimates derived from the THIN database and the systematic literature reviews confirms the robustness of the literature-based estimate.Table 6Prevalence of anal fistulas based on analysis of data from the UK THIN database2017201620152014Active patients, *n*3,172,9223,569,5354,219,5774,875,428Patients with anal fistula, *n*^a^5796889381143Total per 10,000 population1.821.932.222.34UK standardized estimate per 10,000 population (95% CI)^b^1.80 (1.65--1.94)1.89 (1.75--2.03)2.19 (2.05--2.33)2.31 (2.18--2.44)EU standardized estimate per 10,000 population (95% CI)^c^1.83 (1.68--1.98)1.94 (1.79--2.08)2.23 (2.08--2.37)2.36 (2.22--2.50)Mid-year point prevalence calculated on the basis on the number of prevalent cases of anal fistula as of July 1 each year and the number of active patients on July 1 of the corresponding year*CI* confidence interval^a^Includes anal fistulas within the previous 12 months in patients without Crohn's disease and anal fistulas within the previous 4 years in patients with Crohn's disease^b^Stratified by age and sex, and standardized to the UK population based on 2016 census data   \[[@CR33]\]^c^Stratified by age and sex, and standardized to the EU populations based on 2013 population estimates \[[@CR34]\]

Discussion {#Sec12}
==========

The present study represents the first systematic literature reviews and corroborative analysis of a large, population-based database to ascertain the prevalence of anal fistulas in Europe. The findings suggest that the prevalence of anal fistulas is 1.69/10,000 population, with an annual incidence of 1.15/10,000 population. According to the threshold definition of 5/10,000 population established by the European Medicines Agency, the estimated prevalence of anal fistulas meets the criteria for a rare condition \[[@CR64]\].

A substantial majority of prevalent cases of anal fistulas were either of cryptoglandular origin or secondary to CD (more than 95%); a variety of etiologies, including infection, trauma, cancer, and congenital malformation, account for the remaining 5%. While anal fistulas have occasionally been reported in patients with certain infections, diabetes, ulcerative colitis, and diverticulitis, such cases are extremely rare. In terms of incidence, cryptoglandular fistulas were clearly predominant compared with CD-related fistulas (75% vs 18%), whereas prevalence rates were relatively balanced (51% vs 45%). Such differences were driven by the longer duration and high-level relapse of anal fistulas in CD.

The strengths of the present study include the performance of two separate literature reviews by independent reviewers and use of a large population-based database as a validation dataset. Population-based data sources are considered the gold standard for epidemiologic analyses. In the present analysis, prevalence estimates from population-based data sources were adjusted to account for differences in the duration of anal fistulas according to etiology, and results from the database were stratified by age and sex to facilitate extrapolation to the European population. Importantly, the close agreement between the estimates derived from the literature reviews and population-based database analysis provided compelling corroborative evidence to support the robustness of the findings.

The present findings should be interpreted in the context of certain limitations, including the limited number of studies with suitable data to support estimation of the prevalence of certain etiologies of anal fistulas, and the low number of patients included in some studies. Given the scarcity of epidemiological data, the authors assumed that the identified papers from the first literature search would be significantly heterogeneous, not only in terms of study design and reported epidemiology outcomes but also in terms of quality. As such, a formal comparative assessment of quality/bias was not conducted. For the second literature search, the risk of bias in the identified studies was assessed and, as expected, wide heterogeneity (percentages of items at high risk of bias in the different studies ranged from 0 to 60%) was reported. As such, heterogeneity in the risk of bias between studies is a limitation of this study. Additionally, it should be considered that the average duration of anal fistulas in CD used to estimate the prevalence of this fistula etiology comes from a study conducted in the pre-biologic era, and thus it cannot be ruled out that the average duration has changed. Finally, the analysis of data from the population-based primary care database was subject to potential bias due to misclassification or underreporting of diagnoses and procedures.

Conclusions {#Sec13}
===========

It was estimated from the published literature that the prevalence of anal fistulas in Europe is 1.69/10,000 population. The robustness of this estimate was confirmed by analysis of data from a population-based database (1.83/10,000 population).
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